Research Biobank From Neuromuscular Biopsy Residues (in the Context of Care)

Neuromuscular Diseases Clinical Trial

— COLMYONEU  

Official title:

Constitution of a Collection of Residues of Neuromuscular Biopsies From Patients Taken as Part of Their Health Care at the Bordeaux University Hospital for Neuromuscular Disease and Use for Research Projects

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06074822
• Other study ID #: CHUBX 2023/26
• Status: Recruiting
• Start date: June 26, 2023
• Est. completion date: June 25, 2053

Study information

• Verified date: August 2023
• Source: University Hospital, Bordeaux
• Contact: Marie Laure NEGRIER, Pr
• Phone: 0557821818
• Email: marie-laure.martin-negrier[@]chu-bordeaux.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Neuromuscular diseases are rare diseases for which significant progress has been made in the context of diagnosis thanks to advances in molecular techniques, but the intimate mechanisms of lesion formation remain poorly understood. Advances in cellular and molecular biology, the development of a few animal models, such as transgenic mice, which make it possible to mimic human pathology have made it possible to better understand the physiopathology of these diseases. However, they still do so very imperfectly and incompletely, making it even more necessary than ever to study diseased human muscle tissue to find new avenues of research or to confirm results obtained by experimentation.

The purpose of this collection of tissue samples for neuro-muscular purposes is to collect such samples under the best conditions in order to promote basic and translational research on muscle diseases.

This is why the CHU de Bordeaux wishes to keep the remainders of samples taken as part of the treatment to constitute a collection of biological samples and associated data kept according to quality standards and in compliance with the regulations in force.

Description:

The "COLMYONEU" project is a project to collect leftover frozen neuromuscular biopsy samples from patients taken as part of their health care at the Bordeaux University Hospital for neuromuscular disease.

Its main objective is to store, under the conditions of the CRB standard, residual biological samples from patients with neuromuscular symptoms.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: June 25, 2053
• Est. primary completion date: June 25, 2053
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion criteria

• Patients treated at Bordeaux University Hospital (neurology services, neuropediatrics), rheumatology, medical genetics for suspected neuromuscular disease.

• Men and women are affected, adults and minors.

Exclusion criteria

• no exclusion criteria

Related Conditions & MeSH terms

• Muscle
• Nerve
• Neuromuscular Diseases

Intervention

Other:
• Residual neuromuscular biopsy
recovery of residual neuromuscular biopsy (nerve ans muscle)

Locations

Country	Name	City	State
France	Université Hospital, Bordeaux	Bordeaux

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Constitution of a biocollection	Collection of leftover frozen neuromuscular biopsy samples from patients taken as part of their health care at the Bordeaux University Hospital for neuromuscular disease.	30 years